Perfil de usuários com prescrição de omeprazol em uma Unidade Básica de Saúde do Sul do Brasil: considerações sobre seu uso racional

Priscila Hipólito; Bruno Simas da Rocha; Francisco Jorge Arsego Quadros de Oliveira

doi:10.5712/rbmfc11(38)1153

Authors

Priscila Hipólito Faculdade de Farmácia Universidade Federal do Rio Grande do Sul
Bruno Simas da Rocha Seção de Farmácia Clínica Hospital de Clínicas de Porto Alegre
Francisco Jorge Arsego Quadros de Oliveira Departamento de Medicina Social Universidade Federal do Rio Grande do Sul

DOI:

https://doi.org/10.5712/rbmfc11(38)1153

Keywords:

Omeprazole, Drug Prescriptions, Health Centers

Abstract

Introduction: Proton pump inhibitors (PPIs) are one of the most prescribed therapeutic classes worldwide. Omeprazole, a PPI, is included in the essential medicines list. Studies indicate that short-term use of PPIs can be safe, but that their long-term use is associated with adverse effects. Objective: To evaluate the profile of patients prescribed omeprazole at a Basic Health Unit (BHU) and to evaluate the duration of use, prescribed dose, and indication for use. Methods: This was a cross-sectional study. The medical records of patients prescribed omeprazole in May 2014 were identified by the pharmacy of the BHU, and were reviewed. Results: Of the 349 patients included, 75.4% were female patients and the average age was 64.6 years. The average number of drugs prescribed was 4.5 per patient. A dose of 20 mg was prescribed most frequently (69.8%), and 84.3% of patients had been prescribed omeprazole for more than six months. Gastro-esophageal reflux disease and gastric ulcers were the most cited indications for use. However, in 29.5% of the patients in the medical records examined, no indication for the use of omeprazole could be found. Conclusion: Older age and the number of prescription drugs were associated with increased omeprazole use. These factors can also be associated with irrational, and sometimes unjustified, use of omeprazole, and with its prolonged use.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Chen J, Yuan YC, Leontiadis GI, Howden CW. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol.

;46(2):93-114. DOI: http://dx.doi.org/10.1097/MCG.0b013e3182333820 DOI: https://doi.org/10.1097/MCG.0b013e3182333820

Micromedex® Truven Health Analytics. V.2.0. DRUGDEX System. The Healthcare Business of Thomson Reuters, 2015.

[acesso 8 Ago 2015]. Disponível em: http://www.micromedexsolutions.com/home/dispatch

Wolters Kluwer. Omeprazole: Drug Information. In: Up To Date. [acesso 10 Ago 2015]. Disponível em: http://www.uptodate.

com/contents/omeprazoledruginformation?source=search_result&search=omeprazole&selectedTitle=1%7E150

Brasil. Ministério da Saúde. Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Departamento de Assistência

Farmacêutica e Insumos Estratégicos. Uso Racional de Medicamentos: temas selecionados. Brasília: Ministério da Saúde;

Brasil. Ministério da Saúde. Relação Nacional de Medicamentos Essenciais: RENAME 2014. 9a ed. Brasília: Ministério da

Saúde; 2015.

World Health Organization. WHO Model List of Essential Medicines. [acesso 4 Ago 2015]. Disponível em: http://www.who.

int/selection_medicines/list/en/

Hoefler R, Leite BF. Segurança do uso contínuo de inibidores da bomba de prótons. Farmacoterapêutica. 2009;14(1-2):1-3.

Lima APV, Neto Filho MA. Efeitos em longo prazo de inibidores da bomba de prótons. Braz. J Surg Clin Res. 2013:5(3):45-9.

Caricol FC. Seguridad del omeprazol: ¿es adecuada la duración de los tratamientos? Farm Comunitarios. 2015;7(1):5-9. DOI: https://doi.org/10.5672/FC.2173-9218.(2015/Vol7).001.02

Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev

Clin Pharmacol. 2013;6(4):443-51. DOI: http://dx.doi.org/10.1586/17512433.2013.811206 DOI: https://doi.org/10.1586/17512433.2013.811206

García Rodríguez LA, Ruigómez A, Panés J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin

Gastroenterol Hepatol. 2007;5(12):1418-23. DOI: http://dx.doi.org/10.1016/j.cgh.2007.09.010 DOI: https://doi.org/10.1016/j.cgh.2007.09.010

Souza IKF, Silva AL, Araújo Júnior A, Santos FCB, Mendonça BPCK. Análise qualitativa das alterações anatomopatológicas

na mucosa gástrica decorrentes da terapêutica prolongada com inibidores da bomba de prótons: estudos experimentais

x estudos clínicos. Arq Bras Cir Dig. 2013;26(4):328-34. DOI: http://dx.doi.org/10.1590/S0102-67202013000400015 DOI: https://doi.org/10.1590/S0102-67202013000400015

Yanagihara GR, de Paiva AG, Neto MP, Torres LH, Shimano AC, Louzada MJ, et al. Effects of long-term administration of

omeprazole on bone mineral density and the mechanical properties of the bone. Rev Bras Ortop. 2015;50(2):232-8. DOI: DOI: https://doi.org/10.1016/j.rboe.2015.03.002

http://dx.doi.org/10.1016/j.rbo.2014.05.012 DOI: https://doi.org/10.1016/j.rbo.2014.05.012

Menegassi VS, Czeczko LEA, Czekzo LSG, Ioshi SO, Pisani JC, Ramos Junior O. Prevalência de alterações proliferativas

gástricas em pacientes com uso crônico de inibidores de bomba de prótons. Arq Bras Cir Dig. 2010;23(3):145-9. DOI:

http://dx.doi.org/10.1590/S0102-67202010000300003 DOI: https://doi.org/10.1590/S0102-67202010000300003

Ameijeiras AH, González BC, Zúñiga VL. Prevalencia de prescripción-indicación de protectores gástricos en pacientes

hospitalizados. Gac Sanit. 2007;21(5):412-5. DOI: http://dx.doi.org/10.1157/13110449 DOI: https://doi.org/10.1157/13110449

Palazón EM, Moreno CB. Inhibidores de la bomba de protones, ¿la protección mal entendida? FMC Form Med Contin

Aten Prim. 2011;18(5):243-5.

Centro de Informação sobre Medicamentos. Uso Racional de omeprazol. Alerta terapêutico – Junho 2009. [acesso 10 Ago

. Disponível em: http://www.prefeitura.sp.gov.br/cidade/secretarias/upload/saude/arquivos/assistenciafarmaceutica/omeprazol.pdf

Patterson SM, Cadogan CA, Kerse N, Cardwell CR, Bradley MC, Ryan C. Interventions to improve the appropriate use of

polypharmacy for older people. Cochrane Database Syst Rev. 2014;10:CD008165.

Schroeter G, Chaves LL, Engroff P, Faggiani FT, DE Carli GA, Morrone FB. Estudo de utilização de anti-ulcerosos na

população Idosa de Porto Alegre, RS, Brasil. Rev HCPA. 2008;28(2):89-95.

López-Dóriga Bonnardeaux P, Neira Álvarez M, Mansilla Laguía S. Inhibidores de la bomba de protones: estudio de

prescripción en una Unidad de Recuperación Funcional. Rev Esp Geriatr Gerontol. 2013;48(6):269-71. DOI: http://dx.doi. DOI: https://doi.org/10.1016/j.regg.2013.07.004

org/10.1016/j.regg.2013.07.004

Rozenfeld S. Prevalência, fatores associados e mau uso de medicamentos entre os idosos: uma revisão. Cad Saúde

Pública. 2003;19(3):717-24. DOI: http://dx.doi.org/10.1590/S0102-311X2003000300004 DOI: https://doi.org/10.1590/S0102-311X2003000300004

Moraes-Filho JP, Chinzon D, Eisig JN, Hashimoto CL, Zaterka S. Prevalence of heartburn and gastroesophageal reflux

disease in the urban Brazilian population. Arq Gastroenterol. 2005;42(2):122-7. PMID: 16127569 DOI: http://dx.doi. DOI: https://doi.org/10.1590/S0004-28032005000200011

org/10.1590/S0004-28032005000200011

Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am. 2014;43(1):161-73. PMID: 24503366 DOI: http:// DOI: https://doi.org/10.1016/j.gtc.2013.11.009

dx.doi.org/10.1016/j.gtc.2013.11.009

Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a

systematic review. Fam Pract. 2014;31(6):625-30. DOI: http://dx.doi.org/10.1093/fampra/cmu050 DOI: https://doi.org/10.1093/fampra/cmu050